Skip to main content
U.S. flag

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Find more clinical trials

AVP-786 for Moderate-to-Severe Agitation in People With Alzheimer's Disease

Start: July 8, 2020
End: December 2024
Enrollment: 750

What Is This Study About?

This Phase 3 clinical trial will evaluate the effects and safety of AVP-786, to treat people with moderate-to-severe agitation due to Alzheimer's disease. AVP-786 is a combination of a drug approved by the FDA as a cough suppressant and a second drug which makes the first last longer in the body. Initially, all participants will undergo a screening evaluation to remove anyone whose agitation symptoms can be reduced without medication. The remaining participants will be randomly assigned to take either AVP-786 or a placebo, by tablet, twice a day for up to 12 weeks. Researchers will monitor participants for any side effects and measure changes in the severity of the agitation, including the types and frequency of behaviors.

Do I Qualify To Participate in This Study?

Minimum Age: 50 Years

Maximum Age: 90 Years

Must have:

  • Diagnosis of probable Alzheimer's disease
  • Significant, moderate-to-severe agitation that interferes with daily routine for at least two weeks prior to study screening
  • Availability of a reliable caregiver who:
    • spends a minimum of two hours each day at least four days a week with the participant
    • is willing and able to comply with all study procedures, including daily administration of the study drug to the participant

Must NOT have:

  • Dementia that is due to another condition or disease, other than Alzheimer's disease (e.g., vascular dementia, frontotemporal dementia, Parkinson's disease, substance-induced dementia)
  • Agitation symptoms due to another condition or disease, other than Alzheimer's  (e.g., secondary to pain, other psychiatric disorder, delirium)
  • Agitation symptoms that can be managed without medication
  • Clinically significant or unstable condition or diseases that could interfere with the study, including:
    • Malignant cancer
    • Uncontrolled diabetes
    • Uncontrolled high blood pressure
    • Unstable heart, kidney, or liver disease
    • Diagnosis of myasthenia gravis

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

Study Contact
Otsuka Call Center

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Alabama
Clinical Research Site
Birmingham, AL 35294
Recruiting
Arkansas
Clinical Research Site #840-081
Fort Smith, AR 72901
Recruiting
Clinical Research Site
La Jolla, CA 92093
Recruiting
Clinical Research Site
Oceanside, CA 92056
Recruiting
Clinical Research Site #840-064
Pasadena, CA 91105
Recruiting
Florida
Clinical Research Site
Atlantis, FL 33462
Recruiting
Clinical Research Site
Coral Gables, FL 33134
Recruiting
Clinical Research Site
Doral, FL 33166
Recruiting
Clinical Research Site
Jacksonville, FL 32256
Recruiting
Clinical Research Site
Kissimmee, FL 34744
Recruiting
Clinical Research Site #840-069
Maitland, FL 32751
Recruiting
Clinical Research Site
Miami, FL 33126
Recruiting
Clinical Research Site
Miami, FL 33175
Recruiting
Clinical Research Site
Miami, FL 33467
Recruiting
Clinical Research Site
Orlando, FL 32819
Recruiting
Clinical Research Site #840-079
Tampa, FL 33614
Recruiting
Maryland
Clinical Research Site #840-049
Glen Burnie, MD 21061
Recruiting
Mississippi
Clinical Research Site
Hattiesburg, MS 39401
Recruiting
Clinical Research Site
West Long Branch, NJ 07764
Recruiting
Ohio
Clinical Research Site
Canton, OH 44718
Recruiting
Tennessee
Clinical Research Site
Cordova, TN 38018
Recruiting

Who Sponsors This Study?

Lead: Otsuka Pharmaceutical Development & Commercialization, Inc.

Source: ClinicalTrials.gov ID: NCT04408755

alzheimers.gov

An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health